Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-10-06
DOI
10.1038/s41467-017-00834-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Simultaneous determination of triptolide, tripterifordin, celastrol and nine sesquiterpene alkaloids in Tripterygium preparations using high-performance liquid chromatography–triple quadrupole mass spectrometry
- (2016) Heng Luo et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Cellular distribution of injected PLGA-nanoparticles in the liver
- (2016) Jin-Kyu Park et al. Nanomedicine-Nanotechnology Biology and Medicine
- Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers
- (2015) Xiaoli Yi et al. MOLECULAR PHARMACEUTICS
- Tanshinone II a protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway
- (2014) Wei Li et al. Chinese Journal of Integrative Medicine
- Mechanistic Studies of a Novel Mycophenolic Acid–Glucosamine Conjugate That Attenuates Renal Ischemia/Reperfusion Injury in Rat
- (2014) Xiaohong Wang et al. MOLECULAR PHARMACEUTICS
- Coencapsulated Doxorubicin and Bromotetrandrine Lipid Nanoemulsions in Reversing Multidrug Resistance in Breast Cancer in Vitro and in Vivo
- (2014) Xi Cao et al. MOLECULAR PHARMACEUTICS
- Targeting Therapeutics to the Glomerulus With Nanoparticles
- (2013) Jonathan E. Zuckerman et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol
- (2012) Yulun Huang et al. ANTI-CANCER DRUGS
- Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future
- (2012) J R Senior CLINICAL PHARMACOLOGY & THERAPEUTICS
- Mesangial cell biology
- (2012) Hanna E. Abboud EXPERIMENTAL CELL RESEARCH
- Drug targeting to the diseased liver
- (2012) Klaas Poelstra et al. JOURNAL OF CONTROLLED RELEASE
- Treatment of IgA Nephropathy: An Update
- (2011) Jennifer L Rosselli et al. ANNALS OF PHARMACOTHERAPY
- Nanotechnology for therapy and imaging of liver diseases
- (2011) L. Harivardhan Reddy et al. JOURNAL OF HEPATOLOGY
- Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies
- (2011) Tore-Geir Iversen et al. Nano Today
- Targeting kidney mesangium by nanoparticles of defined size
- (2011) C. H. J. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mesangial pathology in glomerular disease: targets for therapeutic intervention☆
- (2010) Yogesh M. Scindia et al. ADVANCED DRUG DELIVERY REVIEWS
- Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer
- (2010) Radhamani Kannaiyan et al. CANCER LETTERS
- Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio)
- (2010) Sifeng Wang et al. DRUG AND CHEMICAL TOXICOLOGY
- Meta-Analysis of Tripterygium Wilfordii Hook F in the Immunosuppressive Treatment of IgA Nephropathy
- (2010) Yi-Zhi Chen et al. INTERNAL MEDICINE
- siRNA-Based Therapy Ameliorates Glomerulonephritis
- (2010) H. Shimizu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started